

# Implementation of an anticipated reconstitution circuit, and reconstitution modalities of cyclophosphamide vials using a PharmashakerV3©

T.Neocleous<sup>1</sup>, M.Sangnier<sup>1</sup>, J-M. Bernadou<sup>1</sup>, G. Bouguéon<sup>1,2</sup>, A.Berroneau<sup>1</sup>,  
<sup>1</sup> Pharmaceutical Technology Department, Bordeaux University Hospital, Avenue de Magellan, 33604 Pessac, France  
<sup>2</sup> ARNA Laboratoire ChemBioPharm U1212 INSERM - UMR 5320 CNRS, Université de Bordeaux, France

## Introduction

In our sterile production unit (SPU) approximately 26 vials of cyclophosphamide (CYP) 1000mg are reconstituted per week

### Occuring issues:

- Long dissolution of CYP
- Contributes to the development of musculoskeletal disorders
- Impact on production flow and preparation quality



## Objectives

- ✓ Study the feasibility of an early reconstitution of CYP vials using a PharmashakerV3© (PS)
- ✓ Study the reconstitution modalities in order to fluidify the circuit while guaranteeing the handler's comfort and the patient's safety

## Material and methods


### Feasibility:

- List the possible scenarios based on the UPS organization
- Rate the advantages and disadvantages at a multidisciplinary meeting
  - -2 = major negative impact on activity
  - +2 = major positive impact on activity

### Reconstitution and shaking of the CYP vials:

- Manually or via the PS for 2, 4 and 6 minutes (3 vials per method)
- Visual check at the end of shaking → repeat the procedure in the event of incomplete dissolution

### Assessed by High Performance Liquid Chromatography method (HPLC-UV) (1) (C18 RP; H20/ACN 50/50; 50mmx4mmx3µm; 200nm).



### Controls 3 parameters:

- ✓ Average conformity
- ✓ Standard deviation
- ✓ Coefficient of variation

## Results

Description	Advantages	Disadvantages	Average rating
<u>URC1</u> Scenario n°1 PS in isolator	- ↓ risk of microbiological contamination and handling accidents - Optimization of production time - No need for additional formation - One sterilisation	- PS sterilisation - cluttered isolator	+ 5
<u>URC1</u> <u>URC2</u> Scenario n°2 Reconstitution in isolator → PS in sterile hood Agitation	- Uncluttered isolator - Agitation programmable by non-handling personnel - Staff training in sterile dressing	- Additional precautions (cross-contamination) - Sterile dressing - cluttered isolator - Moving between two different rooms - Several sterilisations	- 5,5
<u>URC2</u> Scenario n°3 Reconstitution and agitation in sterile hood	- Uncluttered isolator - Sterile hood handling training - Staff training in sterile dressing - One sterilisation	- Additional precautions (cross-contamination) - Staff unavailable during handling - cluttered isolator - Sterile dressing - Double visual control	-9,25

Vials conservation : 4°C



	Manual	2x2min	4min	6min
Average conformity	96,13%	97,83%	96,359%	96,545
Standard deviation	1,121	0,294	5,067	3,941
Coefficient of variation	0,012	0,003	0,053	0,041

### A better result was obtained with 2x2min method:

- ✓ higher average compliance
- ✓ lower standard deviation
- ✓ lower coefficient of variation

### To note:

- ✓ Only the 2 minutes method required repetition to be successful

## Discussion

- This project enabled us to set up an early reconstitution of CYP in our UPS **according to the procedure in scenario 1:**
  - Reconstitution in an isolator, shaking on PS in an isolator then kept vials at 4°C.
  - After **multidisciplinary evaluation**, scenario 1 appears to be the most suitable in terms of **organization and staff protection.**
- A similar quality of dissolution to manual shaking was noted (**average in our SPU : 3min40**), **with the 2 minutes repeated method.**
- This method allows us :
  - ✓ To **observe the progress** of the dissolution
  - ✓ **Turn the bottle** upside down between each procedure to **homogenise the contents**
  - ✓ Limit the **aggregates' formation**
- The introduction of **PS in our SPU limited TMS** and associated with a **human action**, optimizes the **dissolution** and fluidify the **production.**  
 → It remains to be seen if this process can be applied to **other products** in the future, **in SPU or other services.**